- Home
- Unlocking the immune system
Unlocking the immune system
Our bodies have the amazing capacity to heal when stimulated or activated properly. At Johnson & Johnson, we are advancing scientific and technological solutions that accelerate healing, recalibrate, or modify the body’s own immune system so it is best equipped to heal. By unlocking the complex science of the immune system, our discoveries are changing lives.
Innovating in Health&Care
The future of immunology
Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.
“Patients are the center of everything": Meet the scientist leader dedicated to developing effective IBD treatments
Her natural curiosity, determination and fascination with science inspired Esi Lamousé, M.D., Ph.D., to pursue a career that’s helped bring innovative therapies for inflammatory bowel disease to patients in need around the world.
Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD
Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.
What is IL-23?
This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.
Rheumatoid, psoriatic and osteoarthritis—what you need to know about the 3 main types of arthritis
They share similar symptoms, sure. But these three distinct conditions have distinct causes, occur in people of varying ages and have their own treatments. Read on for the key differences.
What’s the difference between IBS and IBD?
These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.
What is low vision?
Low vision isn’t the same as blindness, but navigating daily life with it is still challenging. Learn the facts—plus, the promising treatment innovations that are in the works.
Getting in front of cancer
Every year, roughly 2 million people in the U.S. are newly diagnosed with cancer. But a number of scientific breakthroughs—including ones made at Johnson & Johnson—have dramatically changed what kind of prognosis many of these patients will have.
What is lupus?
Up to 5 million people worldwide live with this complex autoimmune condition, which is more prevalent in women and has a greater disease severity in Latin Americans and patients of African ancestry. Learn how Johnson & Johnson is working to innovate treatments for autoimmune diseases.
What is a rheumatic disease?
More than 200 conditions are classified as rheumatic diseases, including rheumatoid arthritis, lupus and Sjögren’s disease. They tend to affect the joints and connective tissues, causing pain and swelling and impacting quality of life. Here’s what a doctor wants you to know about the different types, symptoms and risk factors—and how Johnson & Johnson is innovating new treatments.
Are super-personalized solutions the future of healthcare?
The goal of precision medicine is to develop individualized treatments based on a patient’s genetic profile. Here’s how Johnson & Johnson is harnessing this cutting-edge field of tailor-made medicine.
More from Johnson & Johnson
Johnson & Johnson to collaborate with the New York Jets to promote better health in the community
Teaming up to support healthcare in the local community and empower residents.
What you need to know about Johnson & Johnson’s 2025 third-quarter earnings
Here’s an infographic breakdown of the company’s third-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.
How Johnson & Johnson is helping healthcare providers remotely monitor and support patient health
Expertise, innovation and insight are fueling the development of remote and AI-powered approaches to healthcare—potentially improving treatment decisions and evolving the way clinical trials are designed and managed.